Your browser doesn't support javascript.
loading
Evaluation of triple negative breast cancer with heterogeneous immune infiltration.
Quintana, Ángela; Arenas, Enrique Javier; Bernadó, Cristina; Navarro, José Fernández; González, Jonatan; Esteve-Codina, Anna; Moliné, Teresa; Marti, Merce; Curigliano, Giuseppe; Schmid, Peter; Peg, Vicente; Arribas, Joaquín; Cortés, Javier.
Afiliação
  • Quintana Á; Breast Cancer Unit, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.
  • Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Bernadó C; Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.
  • Navarro JF; Preclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • González J; Bioinformatics Department, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.
  • Esteve-Codina A; Bioinformatics Department, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.
  • Moliné T; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Marti M; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Curigliano G; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Schmid P; Departament Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Peg V; European Institute of Oncology, IRCCS, Milan, Italy.
  • Arribas J; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
  • Cortés J; Barts Cancer Institute, Queen Mary University London, London, United Kingdom.
Front Immunol ; 14: 1149747, 2023.
Article em En | MEDLINE | ID: mdl-37215143
Introduction: Tumor infiltrating lymphocytes (TILs) are known to be a prognostic and predictive biomarker in breast cancer, particularly in triple negative breast cancer (TNBC) patients. International guidelines have been proposed to evaluate them in the clinical setting as a continuous variable, without a clear defined cut-off. However, there are scenarios where the immune infiltration is heterogeneous that some areas of the patient's tumour have high numbers of TILs while other areas completely lack them. This spontaneous presentation of a heterogeneous immune infiltration could be a great opportunity to study why some tumours present TILs at diagnosis but others do not, while eliminating inter patient's differences. Methods: In this study, we have identified five TNBC patients that showed great TIL heterogeneity, with areas of low (≤5%) and high (≥50%) numbers of TILs in their surgical specimens. To evaluate immune infiltration heterogeneity, we performed and analyzed bulk RNA-sequencing in three independent triplicates from the high and low TIL areas of each patient. Results: Gene expression was homogeneous within the triplicates in each area but was remarkable different between TILs regions. These differences were not only due to the presence of TILs as there were other non-inflammatory genes and pathways differentially expressed between the two areas. Discussion: This highlights the importance of intratumour heterogeneity driving the immune infiltration, and not patient's characteristics like the HLA phenotype, germline DNA or immune repertoire.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article